<<Despite these sizable numbers, I have doubts about the business proposition of developing an ex-US Lovenox biosimilar for the reasons mentioned in #msg-55882487.>>
Yes, but your logic seemed to be chiefly based on the fact that the EMA guidelines require a clinical trial. Don't you think CW Is suggesting that it might be possible, given the US approval, to persuade the EMA to change those guidelines?
Market Data 
Markets 
AI
